tbuckley/cabot-search huggingface dataset:
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection
Authors: Hugh S. Markus, Christopher Levi, Alice King, Jeremy Madigan, John Norris
Journal: JAMA Neurology (2019)

<h3>Importance</h3> Extracranial carotid and vertebral artery dissection is an important cause of stroke, particularly in younger individuals. In some but not all observational studies, it has been associated with a high risk of recurrent stroke. Both antiplatelet agents (APs) and anticoagulants (ACs) are used to reduce stroke risk, but whether 1 treatment strategy is more effective is unknown. <h3>Objective</h3> To determine whether AP or AC therapy is more effective in preventing stroke in cervical dissection and the risk of recurrent stroke in a randomized clinical trial setting. A secondary outcome was to determine the effect on arterial imaging outcomes. <h3>Design, Setting, and Participants</h3> Randomized, prospective, open-label international multicenter parallel design study with central blinded review of both clinical and imaging end points. Recruitment was conducted in 39 stroke and neurology secondary care centers in the United Kingdom and 7 centers in Australia between February 24, 2006, and June 17, 2013. One-year follow-up and analysis was conducted in 2018. Two hundred fifty participants with extracranial carotid and vertebral dissection with symptom onset within the last 7 days were recruited. Follow-up data at 1 year were available for all participants. <h3>Interventions</h3> Randomization to AP or AC (heparin followed by warfarin) for 3 months, after which the choice of AP and AC agents was decided by the local clinician. <h3>Main Outcomes and Measures</h3> The primary end point was ipsilateral stroke and death. A planned per protocol (PP) analysis was performed in patients meeting the inclusion criteria following central review of imaging to confirm the diagnosis of dissection. A secondary end point was angiographic recanalization in those with imaging confirmed dissection. <h3>Results</h3> Two hundred fifty patients were randomized (118 carotid and 132 vertebral), 126 to AP and 124 to AC. Mean (SD) age was 49 (12) years. Mean (SD) time to randomization was 3.65 (1.91) days. The recurrent stroke rate at 1 year was 6 of 250 (2.4%) on ITT analysis and 5 of 197 (2.5%) on PP analysis. There were no significant differences between treatment groups for any outcome. Of the 181 patients with confirmed dissection and complete imaging at baseline and 3 months, there was no difference in the presence of residual narrowing or occlusion between those receiving AP (n = 56 of 92) vs those receiving AC (n = 53 of 89) (<i>P</i> = .97). <h3>Conclusions and Relevance</h3> During 12 months of follow-up, the number of recurrent strokes was low. There was no difference between treatment groups in outcome events or the rate of recanalization. <h3>Trial Registration</h3> ISRCTN.com Identifier:CTN44555237
A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab
Authors: Kenichi Ogiwara, Keiji Nogami, Tomoko Matsumoto, Mariko Noguchi-Sasaki, Tetsuhiro Soeda, Naoki Matsumoto, Michinori Hirata, Midori Shima
Journal: Blood (2018)
Comparison of Outpatient Satisfaction Survey Scores for Asian Physicians and Non-Hispanic White Physicians
Authors: Luis C. Garcia, Sukyung Chung, Lily Liao, Jonathan Altamirano, Magali Fassiotto, Bonnie Maldonado, Paul Heidenreich, Latha Palaniappan
Journal: JAMA Network Open (2019)

Patient satisfaction scores are used to inform decisions about physician compensation, and there remains a lack of consensus regarding the need to adjust scores for patient race/ethnicity. Previous research suggests that patients prefer physicians of the same race/ethnicity as themselves and that Asian patients provide lower satisfaction scores than non-Hispanic white patients.To examine whether Asian physicians receive less favorable patient satisfaction scores relative to non-Hispanic white physicians.This population-based survey study used data from Press Ganey Outpatient Medical Practice Surveys collected from December 1, 2010, to November 30, 2014, which included 149 775 patient survey responses for 962 physicians. Every month, 5 patients per physician were randomly selected to complete a satisfaction survey after an outpatient visit. Hierarchical multivariable logistic regression was used to examine the association between Asian race/ethnicity of the physician and racial/ethnic concordance of the patient with the probability of receiving the highest score on the survey item rating the likelihood to recommend the physician. Statistical analysis was performed from April 2 to August 27, 2018.Physician characteristics included race/ethnicity, sex, years in practice, and proportion of Asian patient responders. Patient characteristics included race/ethnicity, sex, age, and language spoken.The highest score (a score of 5 on a 1-5 Likert scale, where 1 indicates very poor and 5 indicates very good) on the survey item rating the likelihood to recommend the physician on the Press Ganey Outpatient Medical Practice Survey.Of the 962 physicians in this study, 515 (53.5%) were women; physicians had a mean (SD) of 19.9 (9.1) years of experience since graduating medical school; 573 (59.6%) were white, and 350 (36.4%) were Asian. In unadjusted analyses, the odds of receiving the highest score on the survey item rating the likelihood to recommend the physician were lower for Asian physicians compared with non-Hispanic white physicians (odds ratio, 0.78; 95% CI, 0.72-0.84; P < .001). This association was not significant after adjusting for patient characteristics, including patient race/ethnicity. However, Asian patients were less likely to give the highest scores relative to non-Hispanic white patients (odds ratio, 0.56; 95% CI, 0.54-0.58; P < .001), regardless of physician race/ethnicity.This study suggests that Asian physicians may be more likely to receive lower patient satisfaction scores because they serve a greater proportion of Asian patients. Patient satisfaction scores should be adjusted for patient race/ethnicity.
Honesty in Medicine—An Approach to Patients With Cancer Who Initially Reject Conventional Treatment
Authors: Kunal Sindhu
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions
Authors: Christoph Kuppe, Katja Leuchtle, Anton Wagner, Nazanin Kabgani, Turgay Saritas, Victor G. Puelles, Bart Smeets, Samy Hakroush, Johan van der Vlag, Peter Boor, Mario Schiffer, Hermann-Josef Gröne, Agnes Fogo, Jürgen Floege, Marcus Johannes Moeller
Journal: Kidney International (2019)

Beside the classical flat parietal epithelial cells (PECs), we investigated proximal tubular epithelial-like cells, a neglected subgroup of PECs. These cells, termed cuboidal PECs, make up the most proximal part of the proximal tubule and may also line parts of Bowman's capsule. Additionally, a third intermediate PEC subgroup was identified at the junction between the flat and cuboidal PEC subgroups at the tubular orifice. The transgenic mouse line PEC-rtTA labeled all three PEC subgroups. Here we show that the inducible Pax8-rtTA mouse line specifically labeled only cuboidal and intermediate PECs, but not flat PECs. In aging Pax8-rtTA mice, cell fate mapping showed no evidence for significant transdifferentiation from flat PECs to cuboidal or intermediate PECs or vice versa. In murine glomerular disease models of crescentic glomerulonephritis, and focal segmental glomerulosclerosis (FSGS), intermediate PECs became more numerous. These intermediate PECs preferentially expressed activation markers CD44 and Ki-67, suggesting that this subgroup of PECs was activated more easily than the classical flat PECs. In mice with FSGS, cuboidal and intermediate PECs formed sclerotic lesions. In patients with FSGS, cells forming the tip lesions expressed markers of intermediate PECs. These novel PEC subgroups form sclerotic lesions and were more prone to cellular activation compared to the classical flat PECs in disease. Thus, colonization of Bowman's capsule by cuboidal PECs may predispose to lesion formation and chronic kidney disease. We propose that tip lesions originate from this novel subgroup of PECs in patients with FSGS.Graphical abstract
Erythematotelangiectatic rosacea may be associated with a subclinical stage of demodicosis: a case–control study
Authors: F. Forton, V. De Maertelaer
Journal: British Journal of Dermatology (2019)

BackgroundFacial densities of Demodex mites have been observed to be greater in patients with demodicosis and papulopustular rosacea than in healthy control patients. In patients with erythematotelangiectatic rosacea (ETR), this density has been observed to be similar to or greater than that of healthy controls. Erythema and telangiectasia, characteristics of ETR, are often observed among patients with pityriasis folliculorum, a discreet demodicosis, suggesting a possible link between these conditions.
Abstract P3-06-11: Withdrawn
Authors: A-S Hamy, C Val de Lièvre, E Laas, L Darrigues, M Priour, J Guerin, T Balezeau, A Livartowski, J-Y Pierga, L Escalup, B Asselain, R Rouzier, M Lae, D Decroze, A Pinheiro, C Laurent, F Reyal
Journal: Cancer Research (2018)

Abstract This abstract was withdrawn by the authors.
Cerebrovascular Infarcts in the Setting of Disseminated Intravasulcar Coagulation As Presenting Symptom in Acute Promyelocytic Leukemia
Authors: Kathryn Sarah Simon, Catherine R. Caprara, Prachi Kharkhanis, Stephanie Debragga, Sheldon Bolds, Martha L. Arellano, Vamsi Kota, Anand Jillella
Journal: Blood (2017)
Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome–related factor H mutation
Authors: Yoshiyasu Ueda, Takashi Miwa, Daisuke Ito, Hangsoo Kim, Sayaka Sato, Damodar Gullipalli, Lin Zhou, Madhu Golla, Delu Song, Joshua L. Dunaief, Matthew B. Palmer, Wen-Chao Song
Journal: Kidney International (2019)
ECG Challenge: May 27, 2014
Authors: Philip Podrid
Journal: Circulation (2014)

ECG Challenge 2179A 54-year-old man with lung cancer being treated with chemotherapy presents with progressive fatigue, peripheral edema, and lightheadedness.Although the symptoms were felt to be related to the lung tumor, a chest x-ray was obtained, which showed a markedly increased cardiac silhouette.There was no evidence of vascular congestion.A lung tumor in the left upper lobe was observed.An echocardiogram confirmed a significant pericardial effusion with evidence of tamponade.On physical examination, he had significant peripheral edema and neck vein distension.A pulsus paradoxus of 18 mm Hg was noted.What is the diagnosis?To submit your diagnosis, go to http://circ.ahajournals.org/letters/
Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association
Authors: Sarah D. de Ferranti, Julia Steinberger, Rebecca Ameduri, Annette Baker, Holly Gooding, Aaron S. Kelly, Michele Mietus-Snyder, Mark M. Mitsnefes, Amy L. Peterson, Julie St-Pierre, Elaine M. Urbina, Justin P. Zachariah, Ali N. Zaidi
Journal: Circulation (2019)

This scientific statement presents considerations for clinical management regarding the assessment and risk reduction of select pediatric populations at high risk for premature cardiovascular disease, including acquired arteriosclerosis or atherosclerosis. For each topic, the evidence for accelerated acquired coronary artery disease and stroke in childhood and adolescence and the evidence for benefit of interventions in youth will be reviewed. Children and adolescents may be at higher risk for cardiovascular disease because of significant atherosclerotic or arteriosclerotic risk factors, high-risk conditions that promote atherosclerosis, or coronary artery or other cardiac or vascular abnormalities that make the individual more vulnerable to the adverse effects of traditional cardiovascular risk factors. Existing scientific statements and guidelines will be referenced when applicable, and suggestions for risk identification and reduction specific to each setting will be described. This statement is directed toward pediatric cardiologists, primary care providers, and subspecialists who provide clinical care for these young patients. The focus will be on management and justification for management, minimizing information on pathophysiology and epidemiology.
Observational Outcomes or Use of Guideline Recommended Treatments?
Authors: Paul A. Heidenreich
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Sequential CD19- and CD22-CART Cell Therapies for Relapsed B-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Shuangyou Liu, Biping Deng, Yuehui Lin, Zhichao Yin, Jing Pan, Tong Wu, Zhiyong Gao, Yanzhi Song, Yongqiang Zhao, Chunrong Tong
Journal: Blood (2018)
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
Authors: Matthew R. Collinson-Pautz, Wei-Chun Chang, An Lu, Mariam Khalil, Jeannette W. Crisostomo, Pei-Yi Lin, Aruna Mahendravada, Nicholas P. Shinners, Mary E. Brandt, Ming Zhang, MyLinh Duong, J. Henri Bayle, Kevin M. Slawin, David M. Spencer, Aaron E. Foster
Journal: Leukemia (2019)

Successful adoptive chimeric antigen receptor (CAR) T-cell therapies against hematological malignancies require CAR-T expansion and durable persistence following infusion. Balancing increased CAR-T potency with safety, including severe cytokine-release syndrome (sCRS) and neurotoxicity, warrants inclusion of safety mechanisms to control in vivo CAR-T activity. Here, we describe a novel CAR-T cell platform that utilizes expression of the toll-like receptor (TLR) adaptor molecule, MyD88, and tumor-necrosis factor family member, CD40 (MC), tethered to the CAR molecule through an intentionally inefficient 2A linker system, providing a constitutive signal that drives CAR-T survival, proliferation, and antitumor activity against CD19+ and CD123+ hematological cancers. Robust activity of MC-enhanced CAR-T cells was associated with cachexia in animal models that corresponded with high levels of human cytokine production. However, toxicity could be successfully resolved by using the inducible caspase-9 (iC9) safety switch to reduce serum cytokines, by administration of a neutralizing antibody against TNF-α, or by selecting "low" cytokine-producing CD8+ T cells, without loss of antitumor activity. Interestingly, high basal activity was essential for in vivo CAR-T expansion. This study shows that co-opting novel signaling elements (i.e., MyD88 and CD40) and development of a unique CAR-T architecture can drive T-cell proliferation in vivo to enhance CAR-T therapies.
Mannan binding lectin (MBL) is present in human lung tissue and is expressed by human lung mast cells
Authors: Laura Fregonese, Anja Roos, Mohamed R. Daha, Annemarie van Schadewijk, Marisa Dolhnikoff, Teizo Fujita, Pieter S. Hiemstra, Klaus F. Rabe, Thais Mauad
Journal: European Respiratory Journal (2003)
Hsa-miR-122, a tumor suppressor microRNA that regulates intra-hepatic metastasis of hepatocellular carcinoma
Authors: Ann-Ping Tsou, Wei-Chih Tsai, Wei-Che Hsu, Hsien-Da Huang, Gar-Yang Chau, Tsung-Ching Lai, Michael Hsiao Hsiao
Journal: Cancer Research (2009)
Use of 5-0 Fast Absorbing Gut versus 6-0 Fast Absorbing Gut during cutaneous wound closure on the head and neck: A randomized evaluator-blinded split-wound comparative effectiveness trial
Authors: Aunna Pourang, Milene K. Crispin, Ashley K. Clark, April W. Armstrong, Raja K. Sivamani, Daniel B. Eisen
Journal: Journal of the American Academy of Dermatology (2019)
Provincial Disparities in Access to Allogeneic Transplant in Canada
Authors: Kristjan Paulson, Oliver Bucher, Geoffrey Cuvelier, Andrew Daly, Alina S. Gerrie, David Sanford, David Szwajcer, Matthew Seftel, Irwin Walker, Natasha Kekre, Tony H Truong, Donna Wall, Kirk R. Schultz, Stephen Couban, Christopher Bredeson
Journal: Blood (2018)
Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis
Authors: Rajnish Mehrotra, Daniel Cukor, Mark Unruh, Tessa Rue, Patrick Heagerty, Scott D. Cohen, Laura M. Dember, Yaminette Diaz-Linhart, Amelia Dubovsky, Tom Greene, Nancy Grote, Nancy Kutner, Madhukar H. Trivedi, Davin K. Quinn, Nisha ver Halen, Steven D. Weisbord, Bessie A. Young, Paul L. Kimmel, S. Susan Hedayati
Journal: Annals of Internal Medicine (2019)

Although depression is common among patients receiving maintenance hemodialysis, data on their acceptance of treatment and on the comparative efficacy of various therapies are limited.To determine the effect of an engagement interview on treatment acceptance (phase 1) and to compare the efficacy of cognitive behavioral therapy (CBT) versus sertraline (phase 2) for treating depression in patients receiving hemodialysis.Multicenter, parallel-group, open-label, randomized controlled trial. (ClinicalTrials.gov: NCT02358343).41 dialysis facilities in 3 U.S. metropolitan areas.Patients who had been receiving hemodialysis for at least 3 months and had a Beck Depression Inventory-II score of 15 or greater; 184 patients participated in phase 1, and 120 subsequently participated in phase 2.Engagement interview versus control visit (phase 1) and 12 weeks of CBT delivered in the dialysis facility versus sertraline treatment (phase 2).The primary outcome for phase 1 was the proportion of participants who started depression treatment within 28 days. For phase 2, the primary outcome was depressive symptoms measured by the Quick Inventory of Depressive Symptoms-Clinician-Rated (QIDS-C) at 12 weeks.The proportion of participants who initiated treatment after the engagement or control visit did not differ (66% vs. 64%, respectively; P = 0.77; estimated risk difference, 2.1 [95% CI, -12.1 to 16.4]). Compared with CBT, sertraline treatment resulted in lower QIDS-C depression scores at 12 weeks (effect estimate, -1.84 [CI, -3.54 to -0.13]; P = 0.035). Adverse events were more frequent in the sertraline than the CBT group.No randomized comparison was made with no treatment, and persistence of treatment effect was not assessed.An engagement interview with patients receiving maintenance hemodialysis had no effect on their acceptance of treatment for depression. After 12 weeks of treatment, depression scores were modestly better with sertraline treatment than with CBT.Patient-Centered Outcomes Research Institute, Dialysis Clinic, Kidney Research Institute, and National Institute of Diabetes and Digestive and Kidney Diseases.
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy
Authors: Gerald Chi, C. Michael Gibson, Arzu Kalayci, Alexander T. Cohen, Adrian F. Hernandez, Russell D. Hull, Farima Kahe, Mehrian Jafarizade, Sadaf Sharfaei, Yuyin Liu, Robert A. Harrington, Samuel Z. Goldhaber
Journal: Intensive Care Medicine (2019)
Lifetime Occupational Exposure To Vapor, Gases/fumes, Dust And Risk Of COPD At 45 Years: The Tasmanian Longitudinal Health Study (tahs)
Authors: S. M. Alif, S. C. Dharmage, G. Benke, M. Dennekamp, J. Burgess, J. L. Perret, C. J. Lodge, S. Morrison, D. P. Johns, G. G. Giles, P. S. Thomas, R. Vermeulen, H. Kromhout, M. Abramson, E. H. Walters, M. C. Matheson
Journal: American Journal of Respiratory and Critical Care Medicine (2016)
Prognostic and Predictive Impact of Small PNH Clones in a Large Cohort of Patients with Myelodysplastic Syndromes and Aplastic Anemia: A Single-Center Experience
Authors: Bruno Fattizzo, Alan Dunlop, Robin M. Ireland, Shireen Kassam, Dario Consonni, Deborah Yallop, Ghulam J. Mufti, Judith Marsh, Alberto Zanella, Wilma Barcellini, Austin G. Kulasekararaj
Journal: Blood (2018)
Psychological Maltreatment and Medical Neglect of Transgender Adolescents: The Need for Recognition and Individualized Assessment
Authors: Armand H. Matheny Antommaria, Robert A. Shapiro, Lee Ann E. Conard
Journal: The American Journal of Bioethics (2019)

This article refers to:Transgender Children and the Right to Transition: Medical Ethics When Parents Mean Well but Cause Harm
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
Authors: S.T. Kim, J.H. Kang, J. Lee, H.W. Lee, S.Y. Oh, J.S. Jang, M.A. Lee, B.S. Sohn, S.Y. Yoon, H.J. Choi, J.H. Hong, M.-J. Kim, S. Kim, Y.S. Park, J.O. Park, H.Y. Lim
Journal: Annals of Oncology (2019)
Wallace Peters: renowned malariologist who was the first “to really wave the flag” for combination therapy
Authors: Penny Warren
Journal: BMJ (2019)

Wallace Peters grew up in north London, where his parents, Henry and Fanny, had several shops. He was the youngest by nine years, with an older sister, Ronnie, and two half sisters. From an early age, he had an abiding interest in entomology, spending time on Hampstead Heath collecting insects and butterflies. Evacuated in 1939 to Cambridgeshire, he liked to cycle to Wicken Fen to catch glimpses of copper and swallowtail butterflies. During his lifetime, he would collect around 4000 specimens.

Peters attended Haberdashers’ Aske’s Boys’ School and then in 1942 went to Cambridge University to study medicine, where for a time he was interested in communist politics. He completed his medical training at St Bartholomew’s Hospital Medical College, qualifying in 1947. One of his first jobs was as a house surgeon working at Hill End Hospital in Hertfordshire. He treated returning servicemen, some of whom had tropical parasites which, with his interest in entomology, he found fascinating. …